HK2 Polyclonal Antibody

The recommended starting dilution for Western Blot is WB 1:1000-1:5000;IHC 1:100-1:300. Optimal dilution should be determined empirically for each laboratory setup, sample type, and detection system. Use freshly prepared lysates with protease inhibitors; add phosphatase inhibitors if studying phosphorylation-dependent forms of HK2. Expected band size: Calculated 102kDa. If background is high, increase blocking (5% non-fat milk or BSA in TBST) and/or increase wash stringency.

For IHC-P, heat-induced epitope retrieval (HIER) is typically required. Recommended starting conditions: citrate buffer pH 6.0 (microwave or pressure cooker, ~20 min) for rodent samples; EDTA buffer pH 9.0 for human clinical samples. After retrieval, allow sections to cool gradually before proceeding to blocking. Include a HK2-positive tissue control (confirmed by literature or database expression data) and a negative isotype control in every run. Recommended dilution: WB 1:1000-1:5000;IHC 1:100-1:300. Refer to the product datasheet for any target-specific retrieval guidance.

This antibody has been experimentally validated in: Human, Mouse, Rat. Cross-reactivity with other species has not been systematically evaluated. If your sample species is not listed, assess immunogen sequence homology to your target species ortholog. The immunogen used is: "Recombinant protein of human HK2" — higher sequence identity between species increases the probability of cross-reactivity, but experimental validation with appropriate controls is necessary before drawing scientific conclusions.

Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles. Storage Buffer: PBS with 0.05% sodium azide and 50% glycerol, PH7.4. To maintain antibody activity, avoid repeated freeze-thaw cycles. Aliquot into single-use volumes before first freeze. If working with the antibody frequently, keep a working stock at 4°C for up to 4 weeks — add 0.02% sodium azide to the working stock as a bacteriostatic agent if azide is not already present in the buffer. Monitor performance against a validated positive control when transitioning between storage aliquots or lots.

Polyclonal antibodies are produced from immunized animals and may exhibit some degree of lot-to-lot variation in titer, background, and sensitivity. Each production lot is tested for performance against established acceptance criteria. When transitioning to a new lot, run a side-by-side pilot comparison against your previous lot using a validated positive control sample before updating your standard protocol. If significant performance differences are observed, contact our technical support team — titer adjustments may resolve the issue in most cases.